Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors

Oncology

Volumn 79, Issue 1-2, 2010, Pages 55-61

  Motomura, Kazuyoshi ^a   Ishitobi, Makoto ^a   Komoike, Yoshifumi ^a   Koyama, Hiroki ^a   Nagase, Hideki ^c   Inaji, Hideo ^a   Noguchi, Shinzaburo ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; Estrogen receptor ; Estrogen receptor ; Prognostic factor

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FADROZOLE; GOSERELIN; PROGESTERONE RECEPTOR; SERINE; TAMOXIFEN; TOREMIFENE;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FADROZOLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SERINE; TAMOXIFEN; TRIAZOLES;

EID: 78149302577     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319540     Document Type: Article

References (36)

1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
2. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
4. Gustafsson JA: An update on estrogen receptors. Semin Perinatol 2000; 24: 66-69.
5. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-4263.
6. Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA: Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 2000; 55: 63-93.
7. Lannigan DA: Estrogen receptor phosphorylation. Steroids 2003; 68: 1-9.
8. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. Science 1995; 270: 1491-1494.
9. Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996; 15: 2174-2183.
10. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA: pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998; 18: 1978-1984.
11. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-9824.
12. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC, Ali S: Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002; 21: 4921-4931.
13. Murphy L, Cherlet T, Adeyinka A, Niu Y, Snell L, Watson P: Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 2004; 10: 1354-1359.
14. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H: Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 2005; 7:R753-R764.
15. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H: Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 2008; 15: 755-763.
16. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1978.
17. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-3105.
18. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ: Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005; 11: 6598-6607.
19. Halpern J: Maximally selected chi square statistics for small samples. Biometrics 1982; 38: 1017-1023
20. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 1982; 38: 1011-1016.
21. Lausen B, Schumacher M: Maximally selected rank statistics. Biometrics 1992; 48: 73-85.
22. Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, Iwata H, Kobayashi S: Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003; 52(suppl 1):S34-S38.
23. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S, Iwase H: Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 2001; 163: 207-212.
24. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS: Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 2004; 89: 375-383.
25. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H: Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004; 10: 5769-5776.
26. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M: Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001; 32: 113-118.
27. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H: Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 2007; 37: 820-828.
28. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A: The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 2004; 57: 523-528.
29. Myers E, Fleming FJ, Crotty TB, Kelly G, Mc- Dermott EW, O'higgins NJ, Hill AD, Young LS: Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrineresistant breast cancer. Br J Cancer 2004; 91: 1687-1693.
30. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA: Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10: 7490-7499.
31. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH: Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 2002; 87: 1411-1416.
32. O'Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS: Wildtype oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifentreated post-menopausal breast cancers. Br J Cancer 2004; 91: 1694-1702.
33. Markey GC, Cullen R, Diggin P, Hill AD, Mc Dermott EW, O'Higgins NJ, Duffy MJ: Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer. Tumor Biol 2009; 30: 171-175.
34. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H: Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 2009; 100: 2028-2033.
35. Matthews J, Gustafsson JA: Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003; 3: 281-292.
36. Smollich M, Gotte M, Fischgrabe J, Radke I, Kiesel L, Wülfing P: Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. Anticancer Res 2009; 29: 2167-2171.